Swiss Parenterals Limited operates within the pharmaceutical industry, aligning with the acquiring company’s main line of business. The acquisition aims to bolster the acquiring company’s control over the target entity. Remarkably, no governmental or regulatory approvals are necessary for this acquisition, scheduled for completion by September 30, 2024. It involves a cash consideration of INR 237.50 crores in aggregate, with the acquiring company acquiring 4.75% equity shares from four individual promoters, collectively amounting to a 19% shareholding in Swiss Parenterals Limited.
The acquired entity, Swiss Parenterals Limited, specializes in the production of parenteral products. It was incorporated on February 4, 1997. Over the past three years, the company has demonstrated a fluctuating turnover at the group level: Rs. 280.30 crores in FY 2022-23, Rs. 307.70 crores in FY 2021-22, and Rs. 229.53 crores in FY 2020-21. Notably, Swiss Parenterals Limited has a global presence, operating in approximately 80 countries.
As of February 2024, Swiss Parenterals is primarily focused on its dossier-driven sterile injectable business in the RoW (Rest of the World) markets. The company boasts a diverse product range comprising over 190 unique molecules, with an additional pipeline of more than 40 new molecules in development. This extensive product portfolio positions Swiss Parenterals to capitalize on new growth opportunities within its market segment.
In addition to its core sterile injectable business, the company also has a presence in India’s branded injectables market. Furthermore, Swiss Parenterals is involved in the distribution of OSD (Oral Solid Dosage) products in RoW markets, along with the distribution of injectable products in the same regions. These strategic expansions into various segments of the pharmaceutical market demonstrate Swiss Parenterals’ commitment to diversification and sustained growth.